Facts
18. March, 2024
Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions
More than 20 million children annually, alone in Europe, are subject to acute pain...
Releases
29. February, 2024
Annual Report 2023
Cessatech A/S publishes its annual report for the fiscal year 2023, which also includes...
Facts
12. February, 2024
Treating children is not just like treating small adults
Giving medicine to children can’t be a one-size-fits-all approach. Their changing anatomy and...
Releases
9. January, 2024
Cessatech 2024 major milestones and focus
Now is the time – 2024 will be an extremely busy and hopefully exciting...
Releases
4. January, 2024
Q&A session – topline data from Study 0205
Link to release: (Link to Q&A session-image)
Releases
22. December, 2023
Positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001
The study a double-blinded, randomised, placebo-controlled in adults demonstrated that CT001 was superior to...
Releases
25. October, 2023
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children
The European Paediatric Committee (PDCO) has agreed to a 50% reduction in the number...
Releases
21. September, 2023
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001
Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of...
Releases
12. September, 2023
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children
On 12 September – Cessatech A/S (“Cessatech” or “the Company”) announces that EMA’s Paediatric...
Releases
31. August, 2023
August business update
A short update to the great progress we continue to make….thanks for reading!...
Facts
25. August, 2023
New findings supporting CT001
Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...
Releases
24. August, 2023
Second quarter report Q2-2023
US co-development and commercialization partnership signed for CT001 – potential income already from 2024...